Conditions: Rheumatoid Arthritis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 112
Healthy volunteers: no

Brief summary:
This study will evaluate immune response following administration of zoster vaccine in subjects with rheumatoid arthritis who are receiving background methotrexate and initiate 5 mg twice daily of tofacitinib or placebo for tofacitinib 2 to 3 weeks following vaccination.

Detailed description:

Arms:
arm 1: Zoster vaccine will be administered to subjects on background methotrexate; treatment with 5 mg tofacitinib twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks. arm 2: Zoster vaccine will be administered to subjects on background methotrexate; treatment with placebo twice daily will begin 2 to 3 weeks following vaccination and continue for 12 weeks.

Interventions: intervention 1: Tofacitinib intervention 2: Placebo
Intervention descriptions: intervention 1: 5 mg twice daily of tofacitinib with background methotrexate for 12 weeks intervention 2: Placebo tablets twice daily with background methotrexate for 12 weeks

Protocol document: